A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2011
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://ncbi.nlm.nih.gov/pubmed/22198412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1918-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker